Next Article in Journal
Development of Plasmids for Quantitative Detection of Integrated Lentiviral Vectors and Evaluation of Culture Time to Perform Vector Titer by Real-Time Quantitative Polymerase Chain Reaction Assay
Previous Article in Journal
Control of Thalassemia in India
 
 
Thalassemia Reports is published by MDPI from Volume 12 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Development and Recent Progresses of Gene Therapy for β-Thalassemia

by
Santina Acuto
*,
Elena Baiamonte
,
Rosalia Di Stefano
,
Barbara Spina
,
Rita Barone
and
Aurelio Maggio
Santina Acuto, UOC Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Dipartimento di Oncologia ed Ematologia, AO Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy
*
Author to whom correspondence should be addressed.
Thalass. Rep. 2014, 4(2), 2925; https://doi.org/10.4081/thal.2014.2925
Submission received: 21 February 2014 / Revised: 15 April 2014 / Accepted: 20 May 2014 / Published: 29 September 2014

Abstract

β-thalassemias are among the most common inherited monogenic disorders worldwide due to mutations in the β-globin gene that reduce or abolish the production of the β-globin chain resulting in transfusion-dependent chronic anemia. Currently, the only curative treatment is allogeneic hematopoietic stem cells (HSCs) transplantation, but this option is limited by the a vailability of HLA-matched donor. Gene therapy, based on autologous transplantation of genetically corrected HSCs, holds the promise to treat patients lacking a compati ble bone marrow donor. I nit ial attempts of gene transfer have been unsuccessful due to limitations of available vectors to stably transfer a globin gene in HSCs and reach high and regulated expression in the erythroid progeny. With the advent of lentiviral vectors (LVs), based on human immunodeficiency virus, many of the initial limitations have been overcome. Since 2000 when Sadelain and co-workers first demonstrated successful globin gene transfer in murine thalassemia models with improvement of the phenotype using a recombinant β globin/LV, several other groups have developed different vectors encoding either β, γ or mutated globin genes and confirmed these results in both murine models and erythroid progeny derived from patient’s HSCs. In light of these encouraging results, research has recently moved into clinical trials that are ongoing or soon to begin. One participant in an ongoing gene transfer trial for β-thalassemia has achieved clinical benefit with elimination of his transfusi on re quirement. Here , dev elopmen t and recent progress of gene therapy for β-thalassemia is reviewed.
Keywords: gene therapy; β-thalassemia; hematopoietic stem cells; lentiviral vectors gene therapy; β-thalassemia; hematopoietic stem cells; lentiviral vectors

Share and Cite

MDPI and ACS Style

Acuto, S.; Baiamonte, E.; Di Stefano, R.; Spina, B.; Barone, R.; Maggio, A. Development and Recent Progresses of Gene Therapy for β-Thalassemia. Thalass. Rep. 2014, 4, 2925. https://doi.org/10.4081/thal.2014.2925

AMA Style

Acuto S, Baiamonte E, Di Stefano R, Spina B, Barone R, Maggio A. Development and Recent Progresses of Gene Therapy for β-Thalassemia. Thalassemia Reports. 2014; 4(2):2925. https://doi.org/10.4081/thal.2014.2925

Chicago/Turabian Style

Acuto, Santina, Elena Baiamonte, Rosalia Di Stefano, Barbara Spina, Rita Barone, and Aurelio Maggio. 2014. "Development and Recent Progresses of Gene Therapy for β-Thalassemia" Thalassemia Reports 4, no. 2: 2925. https://doi.org/10.4081/thal.2014.2925

Article Metrics

Back to TopTop